The Food and Drug Administration has updated the drug's label, saying that Wegovy can be prescribed to reduce a person's risk of heart attack and stroke, the company said. The label change could mean that more employers and insurers are persuaded to cover the medication.
Heart disease is the leading cause of death in the United States, according to the Centers for Disease Control and Prevention.
The George Washington University has experts available to talk about the drug and its impact on heart attack as well as stroke risk. If you would like to schedule an interview, please contact Katelyn Deckelbaum, [email protected].
Christian Nagy, a practicing cardiologist and assistant professor at the George Washington University School of Medicine and Health Sciences is board-certified in internal medicine, cardiovascular disease, interventional cardiology and adult congenital heart disease.
William Borden is a professor of medicine and health policy at the George Washington University School of Medicine and Health Sciences and chief quality and population health officer at the GW Medical Faculty Associates. He specializes in preventive cardiology and the treatment of high blood cholesterol.
William Dietz is the director of the Sumner M. Redstone Global Center for Prevention and Wellness at the GW Milken Institute School of Public Health. He can talk in detail about the drug and the success rate with weight loss.
-GW-